Pharmaceutical companies in ICC Russia-related arbitration face specific procedural risks. What in-house counsel must know. Make an enquiry.
Unlike English-seated commercial arbitration, where enforcement pathways and interim relief mechanisms are broadly predictable, ICC arbitration in Russia-related commercial disputes confronts in-house counsel with a distinct set of procedural and strategic variables — variables that become considerably more acute in the pharmaceuticals sector. Distribution agreements, licensing arrangements, technology transfer contracts, and supply agreements with Russian counterparties commonly carry arbitration clauses that were drafted before the legal landscape shifted materially. Understanding what those clauses actually deliver — in practice, before a Russian court — is among the more consequential questions facing a pharmaceutical company's legal team in 2026.
Before issuing a Request for Arbitration under the ICC Rules in a Russia-related pharmaceutical dispute, in-house counsel should have confirmed the following:
If you are preparing for ICC arbitration against a Russian pharmaceutical counterparty, an early review of your arbitration clause and counterparty status can determine the strategic options available. Make an enquiry: info@vetrovpartners.com |
Russia-related commercial arbitration in the pharmaceutical sector arises most frequently from three categories of contractual relationship: distribution and exclusive dealership agreements; technology licensing and know-how transfer arrangements; and clinical research organisation contracts or co-development agreements with Russian research institutions. Each category generates a distinct dispute profile.
Distribution disputes typically involve termination claims, unpaid invoices, and post-termination non-compete obligations. The Russian distributor's domestic counsel will commonly raise arguments under Russian competition law — specifically, the rules on dominant market position and arbitrary termination of distribution arrangements — as a substantive defence before an ICC tribunal, even where the contract specifies a foreign governing law. In-house counsel should anticipate this and ensure the arbitral record addresses it directly.
Licensing disputes in pharmaceuticals are more technically complex. They frequently involve questions about the validity and registration status of intellectual property rights in Russia, royalty calculation methodology, and the scope of sub-licensing rights granted to regional distributors. Because Russian IP registration is a matter of Russian administrative law — handled by the Federal Institute of Industrial Property — the tribunal will often need to receive expert evidence on the Russian regulatory position, adding time and cost to proceedings.
Clinical research and co-development disputes are the least common but the most strategically sensitive. They can involve allegations of misappropriation of confidential data, disputes over inventorship under Russian patent law, and — where a Russian research institution holds state funding — questions about government rights in the resulting IP. These matters require careful coordination between ICC arbitration counsel and Russian-qualified lawyers advising on the domestic regulatory dimension.
When a pharmaceutical supply or distribution contract specifies Russian law as the governing law and ICC arbitration as the dispute resolution mechanism, the tribunal will apply Russian substantive law to the merits while the ICC procedural framework governs the conduct of the arbitration. This division is well-established and broadly uncontroversial — but it creates specific practical demands.
First, the parties will typically need to retain Russian law experts to advise the tribunal on the content of applicable Russian law. The standard for expert evidence on foreign law varies by seat: at a Paris-seated tribunal, the approach to foreign law expert testimony is generally more flexible than at certain common law seats. In-house counsel should ensure that the expert mandate is framed precisely — broad mandates on "Russian commercial law" are less useful than targeted instructions on, for example, the specific obligations of an exclusive distributor under Russian civil obligations doctrine.
Second, mandatory Russian law provisions may be treated by the tribunal as overriding norms regardless of the parties' choice of law. Russian consumer protection provisions, certain competition law requirements applicable to pharmaceutical pricing and distribution, and the regulatory requirements governing the import and domestic sale of medicinal products are candidates for treatment as mandatory rules. A well-drafted arbitration agreement, combined with an experienced tribunal, will manage these issues effectively — but in-house counsel should not assume that a choice of, say, Swiss law as the governing law eliminates all engagement with Russian mandatory norms.
Third, Russian courts have, in practice, shown willingness to scrutinise the merits of ICC awards in enforcement proceedings — a practice that technically conflicts with the narrow grounds for refusal under the New York Convention, to which Russia is a party. While the majority of commercially significant awards are ultimately recognised, the process is not automatic, and the timeline for enforcement in Russian state courts has, in many instances, extended well beyond the periods that foreign counsel anticipate.
The pharmaceuticals sector introduces regulatory dimensions that general commercial arbitration practice does not routinely encounter. Several procedural matters deserve specific attention from in-house counsel.
Regulatory approvals as a contractual condition. Many pharmaceutical supply agreements incorporate obligations tied to Russian regulatory milestones — marketing authorisation, inclusion on the list of vital and essential medicines, or registration in the state procurement register. When a dispute arises over termination or non-performance, the question of which party bore the regulatory risk is frequently contested. Tribunals will need to assess this against the background of Russian pharmaceutical regulatory law, which has evolved substantially in the post-2020 period. Expert evidence on the regulatory timeline and the allocation of approval risk under Russian law will often be a central element of the case.
Parallel import and compulsory licensing. Russia's 2022 amendments to intellectual property and competition law introduced new mechanisms for compulsory licensing and parallel importation of pharmaceutical products in defined circumstances. These changes have created a category of dispute in which a foreign pharmaceutical manufacturer challenges Russian regulatory action or the conduct of a distributor operating under a government-backed parallel import scheme. An ICC tribunal will need to grapple with the legal basis and limits of these Russian law instruments when assessing liability and remedy. In-house counsel should expect this to be contested and should build it into the case budget and timeline.
Data and documentation requirements. Russian pharmaceutical contracts generate substantial volumes of regulatory documentation — import permits, quality certificates, registration dossiers, adverse event reports. In discovery and document production phases of ICC proceedings, these records are relevant and frequently dispositive. Ensuring that this documentation has been systematically maintained, and that it is retrievable in a format usable in international arbitration, is a matter that in-house counsel should raise with their local regulatory and compliance teams well before a dispute materialises.
Pricing and state procurement pricing. A significant share of pharmaceutical sales in Russia passes through the state procurement system, which imposes regulated pricing for products on the vital and essential medicines list. Disputes involving reference pricing, maximum trade allowances, and the allocation of pricing risk between a foreign manufacturer and its Russian distributor are highly fact-specific and require an expert who understands both the Russian pricing regulatory framework and the commercial mechanics of the pharmaceutical supply chain.
For in-house counsel, the enforcement question is often the most practically consequential. An ICC award in favour of a foreign pharmaceutical company against a Russian counterparty must be recognised and enforced by a Russian state court — specifically, an arbitrazh court — before it can be executed against Russian-sited assets. The legal framework for recognition is Russia's accession to the New York Convention, supplemented by domestic procedural rules governing the recognition of foreign arbitral awards.
In practice, the process involves filing an application with the arbitrazh court of the region where the respondent is registered or where assets are located, submitting the award and arbitration agreement in certified translation, and responding to any challenge raised by the respondent on the recognised grounds for refusal. Russian courts have applied the public policy exception with varying degrees of breadth — a pattern that makes the enforcement outcome less predictable than the New York Convention text alone would suggest. For pharmaceutical disputes, public policy arguments tied to the supply of essential medicines or state procurement obligations have been raised by respondents, with mixed results.
Foreign creditors who delay initiating enforcement proceedings risk losing the ability to pursue identifiable Russian assets if the counterparty undertakes a restructuring or asset transfer — a window that, under Russian civil and insolvency legislation, can close faster than counsel unfamiliar with the domestic framework would anticipate. Early parallel planning — combining the ICC arbitration with a Russian counsel-led monitoring of the counterparty's financial position and corporate activity — is, in the experience of the firm's Cross-border Disputes & Arbitration practice, among the more effective approaches available to in-house counsel managing a live dispute.
Further analysis of how regulatory developments have affected enforcement strategy is available in our briefing on Roskomnadzor enforcement trends and ICC arbitration strategy and in our note on strategic considerations in ICC arbitration involving Russian counterparties. For matters already in proceedings, a review of the firm's matters experience may assist in identifying analogous procedural situations.
For in-house counsel with an ICC award against a Russian counterparty — or with proceedings imminent — early engagement with Russian enforcement counsel substantially improves the range of available options. Make an enquiry: info@vetrovpartners.com |
When a contractual relationship with a Russian pharmaceutical counterparty deteriorates to the point where arbitration is foreseeable, the sequencing of internal and external steps matters considerably. The following approach reflects practice in matters handled by the firm's disputes team.
First, preserve the record. Before issuing any formal notice, internal correspondence, regulatory communications, and commercial records should be collated and placed under a litigation hold. Russian pharmaceutical contracts generate significant regulatory documentation that is often stored locally within a Russian subsidiary or distributor's systems — in-house counsel should confirm early whether that documentation is accessible and in what format.
Second, assess the counterparty's position in parallel. A Russian counterparty's financial position, corporate structure, and asset base may shift materially during the months that ICC proceedings take. Instructing Russian-qualified counsel to monitor the counterparty's filings with the tax authorities, the Federal Bailiffs Service, and corporate registries provides early warning of restructuring activity that might complicate later enforcement.
Third, review the arbitration clause carefully before issuing the Request for Arbitration. Defects in an arbitration agreement — scope limitations, multi-tier dispute resolution requirements, notice periods — can result in jurisdictional challenges that delay the arbitration by a year or more. If the clause contains a pre-arbitration negotiation or mediation step, compliance must be documented carefully, as Russian respondent counsel routinely raise non-compliance with pre-arbitration steps as a jurisdictional objection.
Fourth, consider interim measures early. ICC arbitration offers emergency arbitrator procedures and, once a tribunal is constituted, interim measures of protection. In Russia-related pharmaceutical disputes, where asset dissipation is a documented risk, in-house counsel should have a considered position on whether to seek interim measures — and, if so, whether to pursue parallel interim relief from a competent national court alongside ICC proceedings.
Fifth, plan the Russian enforcement track from the outset. The selection of arbitral seat, the language of the award, the form of the arbitration agreement, and the procedural conduct of the ICC case all have downstream consequences for enforcement in Russia. Decisions made at the drafting or early arbitration stage that appear neutral can create material obstacles at the enforcement stage. Coordinating ICC arbitration counsel with Russian-qualified enforcement counsel from the beginning of the dispute is the approach most likely to preserve all available options.
Vetrov & Partners acts as Russian enforcement counsel and local arbitration support in ICC proceedings involving Russian counterparties. To discuss your matter — whether at the pre-arbitration, arbitration, or enforcement stage — make an enquiry: info@vetrovpartners.com |
Q: How long does ICC arbitration in a Russia-related pharmaceutical dispute typically take from filing to award?
A: Timelines vary substantially depending on the complexity of the dispute, the number of fact witnesses and experts required, and the parties' conduct of proceedings. In Russia-related pharmaceutical disputes — which commonly involve regulatory expert evidence, document-intensive distribution records, and, in some cases, parallel proceedings in Russian courts — a realistic expectation for a moderately complex case is between 24 and 36 months from the Request for Arbitration to a final award. Simpler contractual disputes involving a discrete payment claim and limited factual issues may resolve in 18 months. In-house counsel should factor in a further period of 6 to 18 months for enforcement proceedings in Russian state courts, which follow the award and are conducted separately.
Q: What documents does a foreign pharmaceutical company need to support an ICC claim against a Russian distributor?
A: The core documentary foundation for a distribution or supply dispute includes the original contract and all amendments, correspondence demonstrating the contractual obligations in dispute, invoices and payment records, shipping and customs documentation, any regulatory approval records relevant to the contractual conditions, and internal records documenting the parties' course of dealing. In pharmaceutical disputes involving pricing or state procurement, records of list prices, maximum trade allowances, and tender participation documentation become relevant. Russian-language originals should be retained alongside translated working copies. Certified translations will be required for submission to both the ICC tribunal and, at the enforcement stage, to the Russian arbitrazh court. In-house counsel should also retain any regulatory filings or communications with Roszdravnadzor or the Ministry of Health that bear on the subject matter of the dispute.
Q: What happens if the Russian counterparty initiates domestic court proceedings in Russia while ICC arbitration is pending?
A: This scenario — sometimes referred to as torpedo litigation — is a recognised tactical risk in Russia-related arbitration. A Russian counterparty may initiate proceedings in a Russian state court seeking a declaration of invalidity of the arbitration clause or requesting that the court assume jurisdiction over the underlying dispute. ICC arbitration is not automatically stayed by parallel Russian proceedings: the tribunal proceeds on the basis of the arbitration agreement and the separability of the arbitral clause. However, in-house counsel must engage Russian-qualified counsel immediately to contest the jurisdiction of the Russian court and to preserve the integrity of the ICC proceedings. Delays in responding to Russian court proceedings — even proceedings that are ultimately unsuccessful — can create procedural complications for both the arbitration timeline and the subsequent enforcement application. Early instruction of Russian counsel to monitor and respond to any parallel domestic filings is standard practice in disputes of this nature.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry